rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Status: Recruiting

This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal cancer after multi-line treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 to 75 years old, regardless of gender advanced gastrointestinal tumors confirmed by histopathology or cytology; patients with gastrointestinal tumors who did not or refused standard treatment at enrollment；Each line of treatment for advanced disease includes one or more drugs for one or more cycles； The pre-permissible treatment was combined with molecular targeted drugs (except endostar)； Patients with previous PD-1 treatment were eligible ECOG-PS score of 0-2 The main organ function was normal and met the following requirements: Blood routine examination (no blood transfusion within 14 days) : a. HB≥80g/L; b. ANC ≥1.5×109/L; c. PLT ≥60×109/L; ② Biochemical examination should meet the following criteria: a. BIL<1.5 times the upper limit of normal (ULN); b. ALT and AST<2.5×ULN; ALT and AST< 5×ULN，if liver metastasis was present; c. Serum Cr≤1×ULN, endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula) predicted survival time ≥3 months Patients voluntarily participated in this study and signed the informed consent form (ICF)  Exclusion Criteria:  hypertensive patients whose blood pressure could not be reduced to normal range by antihypertensive drugs (systolic blood pressure>140 mmHg/diastolic blood pressure >90 mmHg); Patients with ≥ grade Ⅱ coronary artery disease, arrhythmia (including QTc prolongation > 450 ms in men and > 470 ms in women) and cardiac insufficiency patients with active immune diseases abnormal coagulation function (INR>1.5×ULN, APTT>1.5×ULN) with bleeding tendency symptomatic central nervous system metastasis pregnant or lactating women Other patients deemed ineligible for enrollment by the treating physician - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Feasibility of Measuring Vertical Perception in Acute Stroke
Status: Not yet recruiting

The goal of this observational study is to establish if it is feasible to identify vertical perception deficits in people with acute stroke. The primary purpose to the study is:

• To establish the feasibility of completing the Catherine Bergego Scale, Scale for Contraversive Pushing (SCP) and bucket test in a clinical environment with acute stroke patients to assist with identification of vertical perception loss.

Participants will be asked to complete the assessments with a therapist 48 hours after admission. If they are not completed for any reason attempts will be made to complete them at one, two and four weeks after admission. Some participants will have them completed again on discharge. The Catherine Bergego Scale and SCP are observational and will involve a therapist watching the participant undertake daily activities. The bucket test involves a therapist placing a bucket in front of the face of the participant and asking them to identify when a line on the bottom of the bucket is vertical. Acceptabiliy and feasibility will be further investigated using a survey of participants who complete the assessments and through focus groups with the rehabilitation professionals admininstering the assessments.

If it is feasible and acceptable to complete these assessments then further research can use them as an acceptable measure of vertical alignment in the clinical setting.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosis of first stroke by stroke consultant based on clinical or radiographical findings Admitted to stroke unit with a length of stay of over 72 hours Ability to consent or an advocate to consent on their behalf Pre-morbid Modified Rankin Scale of less than 4  Exclusion Criteria:  Under the age of 18 Diagnosis of Transient Ischaemic Attack (TIA) Previous diagnosis of stroke or other neurological diagnosis affecting the brain with residual impairment Patients on an end of life pathway Patients with pre-morbid visual impairment that will not allow them to see the bucket test. Glasses can be worn. Inability to speak the English language and no interpreter can be found - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Acute stroke patients in inpatient care - SamplingMethod: Non-Probability Sample
Outcomes of Proactive Management of Children With Myelomeningocele
Status: Recruiting

Spina bifida birth prevalence in Africa is 0.13%. Myelomeningocele (MMC) represents the most frequent and most severe cause of NB in children. Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Damage of the renal parenchyma in children with NB is preventable given adequate evaluation, follow-up and proactive management. Proactive management was defined as use of clean intermittent catheterization (CIC), and/or anticholinergics at presentation, or based on initial high-risk urodynamic findings by 1 year of age. The proactive approach to treat SB (CIC and pharmacotherapy) has contributed to decreasing chronic kidney disease (CKD). Myelomeningocele is considered a complex congenital disease. Hence, a multidisciplinary team is the best choice for management of spina bifida, involving neurosurgeons, orthopedic surgeons, urologists, physical medicine and rehabilitation specialists and pediatricians. Currently, children with spina bifida in Egypt must visit multiple different locations to access the complex care they need. Here, we review our experience with patients with spina bifida who will be followed with this team with an emphasis on patients' upper urinary tract protection and decreasing urinary incontinence.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  all patients with myelomeningocele attending Assiut university urology hospital.  Exclusion Criteria:  Associated other urological congenital anomalies (e.g., PUV or bladder exstrophy) - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: all patients with myelomeningocele attending Assiut university urology hospital. - SamplingMethod: Non-Probability Sample
Role of Magnesium Sulphate as an Adjuvant to Bupivacaine in U.S Guided Quadratus Lumborum Block in Lower Abdominal Cancer Surgeries
Status: Not yet recruiting

The aim of this study is to assess the efficacy of Mg sulfate ( 10% ) as an adjuvant to Bupivacain ( 0.25 % ) in an U.S guided QLB for postoperative analgesia and postoperative Morphine consumption in lower abdominal cancer surgeries.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age from 18 to 80 years old Both gender Weight from 55 to 85 kg ASA groups 2 and 3 Lower abdominal cancer surgeries  Exclusion Criteria:  1. Patient refusal 2. True local anesthetic allergy 3. Coagulopathy 4. Local infection at the procedure site 5. Psychic patients 6. Patient on chronic opioid use - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
Status: Recruiting

To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients who are suitable for Bridge implantation Symptomatic vertebral artery stenosis with a history of posterior circulation-related ischaemic stroke or TIA despite the use of at least one antithrombotic medications and intervention for risk factors Responsible vertebral artery stenosis (≥70% stenosis, measured by the NASCET method ) confirmed by DSA imaging The patient and/or his/her authorised person understands the purpose of the study, agrees to participate in the study and signs the informed consent form  Exclusion Criteria:  mRS≥3 Presence of tandem stenotic lesions in the target lesion areaor combined basilar artery stenosis Presence of ≥2 stenotic cerebrovascular lesions requiring concurrent intervention The presence of severe tortuosity or calcification of the target vessel, or the presence of extensive abnormal vascular structural variants that are difficult for catheters or stents to pass or cannot be implanted Lesions or stenosis that is too large and beyond the specification of the stent Non-atherosclerotic stenosis such as atrial fibrillation, vasculitis stenosis, arterial entrapment, smoky disease, active phase of arteritis, or unknown cause Contraindication to heparin, aspirin, tegretol, clopidogrel, or other antiplatelet drugs, and those who cannot tolerate anticoagulant and antiplatelet drug therapy Have had intracranial haemorrhage within 3 months Had a myocardial infarction or large cerebral infarction within 2 weeks Accompanied by other intracranial disease such as aneurysm, arteriovenous malformation, intracranial tumour, intracranial infection, etc Presence of active bleeding or extremely dangerous risk of haemorrhage (e.g. active peptic ulcer disease, gastrointestinal lesions with bleeding risk, malignant tumours with bleeding risk, etc.) Severe cardiac, hepatic, splenic, pulmonary, or renal impairment, or allergy or intolerance to contrast media, rapamycin (Rapamycin) and its derivatives, cobalt-based alloys, or polylactic acid - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Oral Enteral Nutrition Feeding in Alzheimer's Patients
Status: Not yet recruiting

This is a prospective multicenter study with Alzheimer's patients with dysphagia. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oral-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age between 18 years and 85 years, meeting the diagnosis of Alzheimer's Disease. presence of no contraindication for enteral nutrition. with dysphagia verified by Imaging materials. with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications Minimum Mental State Examination ranging from 10-26  Exclusion Criteria:  unable to cooperate in completing treatment and assessment due to personal reasons or other disorders. complicated with other intracranial lesions, such as stroke. abnormal structure of swallowing-related organ and tissue. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Effectiveness of Stellate Ganglion Block in Individuals With Parkinson's Disease
Status: Not yet recruiting

The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with Parkinson's disease. The main question it aims to answer are:

• Can stellate ganglion block improve the dysphagia and activities of daily living in patients with Parkinson's disease.

Participants will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age >18 years. Meeting the diagnostic criteria for Parkinson's disease developed by the Neurology Branch of the - - Chinese Medical Association in 2006. Diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. Stable vital signs, conscious, able to cooperate with assessment and treatment.  Exclusion Criteria:  Dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. History of mental diseases or use of antipsychotics. Complicated with cognitive impairment or consciousness dysfunction. Simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease
Status: Not yet recruiting

This is a prospective study conducted on patients with Cerebral Small Vessel Disease, dysphagia and cognitive impairment. They were divided into the comparison group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given Stellate Ganglion Block. The swallowing function, cognitive function and activities of daily living of the two groups of patients before and after treatment were evaluated by Penetration-Aspiration Scale, Mini-mental state examination and modified Barthel index.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age>18 years. Meeting the diagnostic criteria for cerebral small vessel disease. Dysphagia confirmed by Videofluoroscopic Swallowing Study Mini-Mental State Examination (MMSE)<27, indicating the existence of cognitive impairment. No history of prior stroke.  Exclusion Criteria:  Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc. Cognitive impairment that might be caused by other diseases, such as Alzheimer's disease. Neurological blockade contraindications such as bleeding tendency, blocked site infection. Unable to successfully finish the assessment of this study. Complicated with severe liver and kidney failure, tumors, or hematological disorders. Simultaneously in need to undergo other therapy that might affect the outcomes of this study. Pregnant or nursing females - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction
Status: Not yet recruiting

This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, video fluoroscopic swallowing study, and penetration-aspiration scale, Functional Oral Intake Scale, Flexible laryngoscope are used to assess swallowing function.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosed with ischemic stroke according to the diagnostic criteria, with the stroke occurring in the medulla oblongata and diagnosed as bulbar palsy. Upper Esophageal Sphincter did not open or opened ineffectively, with food residue or aspiration, revealed by Videofluoroscopic Swallow Study. Age >18 years. First-time stroke. Steady vital signs, Transferred or admitted to the Department of Rehabilitation Medicine within 15d after onset.  Exclusion Criteria:  The bulbar palsy caused by other diseases, such as neurodegenerative diseases. Pseudobulbar palsy. Complicated with other neurological diseases. Tracheostomy tube inserted. Simultaneously suffering from liver, kidney failure, tumors, or hematological diseases. Dysphagia caused by other possible diseases. Pregnant females. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Effectiveness of Lidocaine Injection on Stellate Ganglion in Pediatric Patients With Autism Spectrum Disorder
Status: Not yet recruiting

The goal of this clinical trial is to explore efficacy of stellate ganglion block Children with Autistic Disorder. The main question it aims to answer is:

Can stellate ganglion block improve the Autistic Disorder in children? Children with Autistic Disorder will be divided into the control group and experimental group evenly. All the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. The Childhood Autism Rating Scale of the two groups of patients before and after treatment are evaluated.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosed as Autistic Disorder. Aged between 3 years old and 6 years old. No contraindications to stellate ganglion block.  Exclusion Criteria:  Other significant physical or neurodevelopmental disorders. Other significant medical conditions - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Years - MaximumAge: 6 Years - StdAgeList: Child
Effect of Oral Enteral Nutrition in Nasopharyngeal Carcinoma Survivors With Swallowing Disorders
Status: Not yet recruiting

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oro-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment as well as adverse events are compared.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age between 30 and 65 years. With the history of Nasopharyngeal Carcinoma and radiation therapy. With dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support. Conscious and with stable vital signs; Willing to participate and sign the written informed consent form either personally or by a family member.  Exclusion Criteria:  Presence of other diseases that might cause dysphagia. With distant metastasis of tumors, or complicated with severe systemic disorders or malignancies. Concurrent participation in other treatments that could interfere with the trial. Inability to cooperate with treatment due to aphasia, mental health issues, etc. Received tube feeding for enteral nutrition support within the past three years. - HealthyVolunteers: No - Gender: All - MinimumAge: 30 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Oral Enteral Nutrition Tube Feeding on Stroke Survivors
Status: Not yet recruiting

The goal of this clinical trial is to explore Clinical Effect of Intermittent Oro-esophageal Tube Feeding in Dysphagic Stroke Survivors. The main questions it aims to answer are:

Can Intermittent Oro-esophageal Tube Feeding improve psychological status in Dysphagic Stroke Survivors? Can Intermittent Oro-esophageal Tube Feeding improve social interaction in Dysphagic Stroke Survivors? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Intermittent Oro-esophageal Tube Feeding as nutrition support and the control group will be given Nasogastric tube. The study lasts 15 days for each patient. Researchers will compare the Social Functioning Scale, Social Support Questionnaire, Patients Health Questionnaire-9, General Anxiety Disorder-7 to see if the Intermittent Oro-esophageal Tube Feeding can help improve the symptom.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age ≥ 18 years; meeting the diagnostic criteria of stroke; any degree of dysphagia at admission; steady vital signs, without severe cognitive impairment or sensory aphasia. transferred out within three weeks of hospitalization in the neurology department.  Exclusion Criteria:  complicated with other neurological diseases; damaged mucosa or incomplete structure in nasopharynx; tracheostomy tube plugged; unfeasible to the support of parenteral nutrition; simultaneously suffering from liver, kidney failure, tumors, or hematological diseases. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Comparison of Oral and Nasal Tube Feeding on Stroke-related Dysphagia
Status: Not yet recruiting

This was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. All patients were given comprehensive rehabilitation therapy. During the treatment, enteral nutrition support was provided for the two groups by Intermittent Oro-esophageal tube feeding and nasogastric tube feeding, respectively. Nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age ≥ 18 years; meeting the diagnostic criteria of stroke; any degree of dysphagia at admission; steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. transferred out within three weeks of hospitalization in the neurology department.  Exclusion Criteria:  complicated with other neurological diseases; damaged mucosa or incomplete structure in nasopharynx; tracheostomy tube plugged; unfeasible to the support of parenteral nutrition; simultaneously suffering from liver, kidney failure, tumors, or hematological diseases. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Intra-articular Injection: A Innovational Approach for Joint Disorder
Status: Not yet recruiting

The goal of this clinical trial is to study about the clinical effect of Intra-articular Injection on Temporomandibular Joint Dysfunction

The main question it aims to answer is:

• Can Intra-articular Injection help improve the Temporomandibular Joint Dysfunction Participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. The experimental group will be given Intra-articular Injection additionally, The study lasts 15 days for each patient. Researchers will compare the assessments between the two groups to see if Intra-articular Injection can help improve the Temporomandibular Joint Dysfunction

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Presence of significant temporomandibular disorder clinical symptoms. Meeting the diagnostic criteria for Temporomandibular Joint Dysfunction and confirmed by X-ray examination. Patients voluntarily participate in this study and provide signed informed consent. Normal cognitive function  Exclusion Criteria:  Rheumatic, rheumatoid, or other severe systemic diseases. Infectious temporomandibular joint arthritis or joint tumors. Individuals who have recently received joint injection treatment or photodynamic therapy. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult